871792-61-9

Basic information

• Product Name: 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine(SALTDATA: 2HCl)
• Synonyms: 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine(SALTDATA: 2HCl)
• CAS NO: 871792-61-9
• Molecular Formula: C₆H₉N₃
• Molecular Weight: 123.15576
• Mol File: 871792-61-9.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine(SALTDATA: 2HCl)(CAS DataBase Reference)
• NIST Chemistry Reference: 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine(SALTDATA: 2HCl)(871792-61-9)
• EPA Substance Registry System: 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine(SALTDATA: 2HCl)(871792-61-9)

Safety Data

• Hazardous Substances Data: 871792-61-9(Hazardous Substances Data)

Usage

General Description

4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine (SALTDATA: 2HCl) is a chemical compound that exists in the form of a salt, specifically as the dihydrochloride salt. It is a heterocyclic compound with a pyrazole and pyridine ring fused together. This chemical is commonly used in research and pharmaceutical applications, particularly in the development of drugs targeting the central nervous system. Its unique structure and properties make it a promising candidate for further studies and potential therapeutic use. As a dihydrochloride salt, it is more stable and water-soluble, making it easier to handle and administer in various applications.

Upstream product

• 271-47-6 1H-pyrazolo[3,4-c]pyridine 
• 40114-49-6 1-benzyl-3-piperidone 

Downstream Products

• 871726-73-7 tert-butyl 1,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate 

Relevant articles and documents

A Continuous Flow Strategy for the Facile Synthesis and Elaboration of Semi-Saturated Heterobicyclic Fragments

An efficient hydrogenation protocol under continuous flow conditions was developed for the synthesis of underrepresented semi-saturated bicyclic fragments containing highly sp3-rich skeletons for fragment-based drug discovery (FBDD) programs. Excellent yields were generally achieved by using Pd/C (10 % w/w) and RaNi at 25–150 °C under 4–100 bar of hydrogen pressure. The generated fragments, with appropriate physicochemical properties, present diverse hydrogen-bonding pharmacophores and useful vectors for their synthetic elaboration in the optimization stage. Successive, simple functionalizations in continuous flow were accomplished to demonstrate the opportunity to develop multi-step continuous flow synthesis of valuable starting points for FBDD campaigns. A conclusive quality control (QC) was essential to discard those structures which do not fit the typical fragment library parameters.